Conversio Health

Conversio Health is dedicated to chronic respiratory disease management, focusing on conditions like COPD and asthma. Their innovative solutions include custom nebulizer medications and smart devices for medication adherence. Founded in 2013 and headquartered in The Woodlands, US, Conversio Health specializes in managing chronic respiratory diseases. The company was established by Taylor Cline, who has a background in healthcare technology.

It has completed one funding round, raising an undisclosed amount in October 2013 from Heritage Group to support its operations. Conversio Health specializes in chronic respiratory disease management, focusing on conditions such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. The company's core offerings include custom nebulizer medications designed to enhance drug delivery and lung penetration, thereby addressing common medication errors among inhaler users. Additionally, Conversio Health provides portable, Bluetooth-enabled smart devices that facilitate real-time medication adherence tracking, including a pocket-sized nebulizer and an inhaler sensor that integrates with any inhaler medication, incorporating a spirometer for quick lung function assessments.

The company also offers a comprehensive COPD self-management program that features tailored exercise videos, health education, and smoking cessation resources, primarily targeting patients with chronic respiratory conditions across the United States. Conversio Health's revenue model revolves around partnerships with healthcare providers and health plans, engaging in direct-to-consumer transactions through subscription models for its respiratory management programs. Clients, including health plans and healthcare providers, collaborate with Conversio Health to ensure effective treatment regimens for patients with COPD and asthma. While specific pricing structures are not disclosed, the flagship products, such as custom nebulizer medications and smart inhaler sensor devices, are integral to its revenue generation strategy.

Conversio Health plans to enhance its product offerings and expand its market presence. The company aims to develop new products, including an upgraded version of their smart inhaler sensor, anticipated for release in late 2024. Additionally, Conversio Health is targeting expansion into new geographic regions, specifically the Midwest and Southeast of the United States by mid-2025. The funding raised in October 2013 will support strengthening relationships with health plans, employers, and government agencies, facilitating greater access to their products and services.